Dermapharm Holding SE Logo

Dermapharm Holding SE

ISIN

DE000A2GS5D8

Ticker

DMP

Sector

Health Care

Sub-Industry

Pharmaceuticals

Country

Germany

Year Founded

1991

About Dermapharm Holding SE

Company Description

Dermapharm is a rapidly growing manufacturer of branded pharmaceuticals. Founded in 1991, the Company is based in GrΓΌnwald near Munich. The Company's integrated business model comprises in-house development, production and the distribution of brand products by a trained pharmaceutical sales force. In addition to its main location in Brehna near Leipzig, Dermapharm also operates other production, development and distribution locations in Europe (primarily in Germany) and the United States.

In the "Branded pharmaceuticals and other healthcare products" segment, Dermapharm has approximately 1,300 marketing authorisations with more than 380 active pharmaceutical ingredients. Dermapharm's portfolio of pharmaceuticals, medical devices and food supplements are tailored to selected therapeutic areas in which the Company is a market leader, especially in Germany.

Headcount

2,373

Served Area

Europe + North America

Headquarters

Lil-Dagover-Ring 7
82031, Grünwald
Germany

Filings & Publications

  • Consolidated Report 2022 - Q1 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2022 - Q1 English πŸ‡¬πŸ‡§
  • Consolidated Report 2022 - Q2 English πŸ‡¬πŸ‡§
  • Consolidated Report 2022 - Q3 English πŸ‡¬πŸ‡§
  • Consolidated Report 2022 - Q4 English πŸ‡¬πŸ‡§
  • Consolidated Report 2021 - Q1 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2021 - Q1 English πŸ‡¬πŸ‡§
  • Consolidated Report 2021 - Q2 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2021 - Q2 English πŸ‡¬πŸ‡§
  • Consolidated Report 2021 - Q3 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2021 - Q3 English πŸ‡¬πŸ‡§
  • Consolidated Report 2021 - Q4 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2021 - Q4 English πŸ‡¬πŸ‡§
  • Consolidated Report 2020 - Q1 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2020 - Q1 English πŸ‡¬πŸ‡§
  • Consolidated Report 2020 - Q2 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2020 - Q2 English πŸ‡¬πŸ‡§
  • Consolidated Report 2020 - Q3 English πŸ‡¬πŸ‡§
  • Consolidated Report 2020 - Q3 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2020 - Q4 English πŸ‡¬πŸ‡§
  • Consolidated Report 2019 - Q1 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2019 - Q1 English πŸ‡¬πŸ‡§
  • Consolidated Report 2019 - Q2 English πŸ‡¬πŸ‡§
  • Consolidated Report 2019 - Q2 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2019 - Q3 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2019 - Q3 English πŸ‡¬πŸ‡§
  • Consolidated Report 2019 - Q4 English πŸ‡¬πŸ‡§
  • Consolidated Report 2019 - Q4 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2018 - Q2 English πŸ‡¬πŸ‡§
  • Consolidated Report 2018 - Q2 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2018 - Q3 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2018 - Q3 English πŸ‡¬πŸ‡§
  • Consolidated Report 2018 - Q4 English πŸ‡¬πŸ‡§
  • Consolidated Report 2018 - Q4 German πŸ‡©πŸ‡ͺ

Insider Trades

Date Trading entity / Person Association Trade type Volume
11.06.2024 Lanz, Susanne Gertrud Pia Close relation Buy EUR 101,778.57
22.05.2024 Themis Beteiligungs-Aktiengesellschaft Close relation Buy EUR 8,577,500.00
27.06.2023 Feldmeier, Dr. Hans-Georg Board Buy EUR 99,902.36
04.04.2023 Dreibholz, Benjamin Close relation Buy EUR 449.28
04.04.2023 Dreibholz, Katharina Close relation Buy EUR 449.04
03.04.2023 Dreibholz, Christof Board Buy EUR 49,024.00
13.01.2023 NEON Equity AG Close relation Buy EUR 16,897.00
11.01.2023 Dreibholz, Christof Board Buy EUR 49,638.00
17.10.2022 Riedel, Oliver Board Buy EUR 11,013.18
17.10.2022 Riedel, Oliver Board Buy EUR 8,650.00

Capital Markets Information

ISIN

DE000A2GS5D8

LEI

5299009F0KNZINQQQK37

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Sub-Industry

Pharmaceuticals

Designated Sponsor

Joh. Berenberg, Gossler & Co. KG

Stifel Europe Bank AG

Listed Stock Exchange

Frankfurt Stock Exchange

Stock Index

SDAX

Contact Investor Relations Department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.